EXAS vs. NTRA, EXEL, DGX, RDNT, GH, FTRE, LH, TFX, CTLT, and QGEN
Should you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Natera (NTRA), Exelixis (EXEL), Quest Diagnostics (DGX), RadNet (RDNT), Guardant Health (GH), Fortrea (FTRE), Laboratory Co. of America (LH), Teleflex (TFX), Catalent (CTLT), and Qiagen (QGEN). These companies are all part of the "medical" sector.
Exact Sciences (NASDAQ:EXAS) and Natera (NASDAQ:NTRA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, community ranking, analyst recommendations, valuation and risk.
Exact Sciences has higher revenue and earnings than Natera. Exact Sciences is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks.
Exact Sciences currently has a consensus price target of $95.40, indicating a potential upside of 89.36%. Natera has a consensus price target of $98.47, indicating a potential downside of 7.51%. Given Exact Sciences' higher probable upside, equities analysts clearly believe Exact Sciences is more favorable than Natera.
Exact Sciences has a net margin of -9.48% compared to Natera's net margin of -30.24%. Exact Sciences' return on equity of -7.12% beat Natera's return on equity.
Exact Sciences received 493 more outperform votes than Natera when rated by MarketBeat users. Likewise, 72.46% of users gave Exact Sciences an outperform vote while only 68.52% of users gave Natera an outperform vote.
In the previous week, Natera had 6 more articles in the media than Exact Sciences. MarketBeat recorded 20 mentions for Natera and 14 mentions for Exact Sciences. Natera's average media sentiment score of 0.76 beat Exact Sciences' score of 0.40 indicating that Natera is being referred to more favorably in the news media.
Exact Sciences has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.
88.8% of Exact Sciences shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 1.3% of Exact Sciences shares are owned by insiders. Comparatively, 7.6% of Natera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Exact Sciences and Natera tied by winning 9 of the 18 factors compared between the two stocks.
Get Exact Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exact Sciences Competitors List
Related Companies and Tools
